Researchers at The University of Texas MD Anderson Cancer Center have developed a new computational approach designed to better account for changes in gene expression within tumors relative to their unique microenvironments. This approach outperformed current methods for predicting chemotherapy response in patients with triple-negative breast cancer (TNBC).
In two new studies on 28,000 individuals, researchers are able to show that genetic variants in 11 regions of the human genome have a clear influence on which bacteria are in the gut and what they do there. Only two genetic regions were previously known. Some of the new genetic variants can be linked to an increased risk of gluten intolerance, hemorrhoids and cardiovascular diseases.
Researchers from the NeuroAD group (Neuropathology of Alzheimer’s Disease) within the Department of Cell Biology, Genetics and Physiology at the University of Málaga, also affiliated with IBIMA–BIONAND Platform and CIBERNED, have made a pioneering breakthrough in the fight against this disease by identifying astrocytes as a promising cellular target for the development of future therapies.
For the first time, researchers, including those from the University of Tokyo, applied a machine learning-based prediction model of insulin resistance to half a million participants from the UK Biobank and demonstrated that insulin resistance is a risk factor for 12 types of cancer.
In the recreation room at Eskaton Village in Carmichael, Bonnie Dale, one of the residents, is trying on a virtual reality (VR) headset.
The specialized sensing layer of the patch targets the tumor necrosis factor-alpha (TNF-⍺) protein, a key biomarker for inflammation.
Philips (NYSE: PHG)+ announced that it launched the InkSpace Imaging Snuggle pediatric body array coil for its 3.0T MRI systems.
Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.
HERAKLION, Greece, Feb. 13, 2026 /PRNewswire/ — EYE PCR announces that its fixOflex endocapsular device has received CE Mark certification under the European Union Medical Device Regulation (EU MDR 2017/745), enabling commercialization in Europe and other markets that recognize the CE Mark. This regulatory milestone validates the device’s safety and efficacy, positioning EYE PCR for controlled market introduction.
GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ — InVera Medical, an Irish medical technology company, has received European regulatory approval for a new minimally invasive device designed to help physicians deliver treatment more effectively to diseased leg veins, including varicose veins.